Announcement • Jun 26

Calidi Biotherapeutics Presents New Data On CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 At The T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics presented data at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment. RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist, a known CD8? T-cell, NK cell, and gamma delta (?d) T-cell activator, in the tumor microenvironment. The Company expects to file an IND for CLD-401 by the end of 2026. Data presented at the T-Cell Therapeutic Engager meeting showcased RedTail viruses that can express both a functional T-cell engager, capable of binding targeted solid tumor cells, and IL-15 superagonist at high concentrations, allowing for simultaneous T-cell activation and high expression in situ of a T-cell engager. T-cell engagers have shown exceptional efficacy in hematological malignancies but have failed to show clinical benefit in solid tumors where the tumor microenvironment inhibits immune cell infiltration and T-cell activity. By remodeling the tumor microenvironment and driving T-cell activation in concert with expression of a T-cell engager, RedTail is designed to overcome these historical limitations. The Company is developing CLD-501, a lead candidate targeting TROP2, a cell-surface glycoprotein. TROP2 expression in normal tissue and the high potential for off-tumor /on-target toxicity has made it a difficult target for T-cell engagers. The RedTail approach confines expression of the T-cell engager to the tumor microenvironment, limiting off-tumor interactions. The Company is pursuing additional T-cell engager targets like EGFR, EpCAM, and Nectin-4. Calidi Biotherapeutics continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.

Announcement • Jun 24

Calidi Biotherapeutics, Inc. Announces Appointment of Corsee Sanders to Board of Directors and Member of the Audit Committee, Effective June 17, 2026

Calidi Biotherapeutics, Inc. announced the appointment of Corazon (Corsee) Sanders, Ph.D., to the Board of Directors, effective June 17, 2026 with a term expiring at the Company’s 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation, retirement, disqualification, or removal. In addition, the Board appointed Dr. Sanders to serve as a member of the Audit Committee of the Board. Corazon (Corsee) D. Sanders, Ph.D., age 69, is a biotechnology executive and board director with more than 30 years of global leadership experience in drug development. She has contributed to the clinical development and regulatory approval of multiple approved therapies. Dr. Sanders currently serves as a Board Director at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), where she is also an Audit Committee member; Legend Biotech Inc. (NASDAQ: LEGN), where she serves on the Audit, Compensation, and Nominating & Governance Committees; and AltruBio Inc. (private), where she is a Board Director and Audit Committee member. Her previous board roles include BeOne Medicines Ltd. (formerly BeiGene Ltd.) (NASDAQ: BGNE), where she served as a Board Director and Audit Committee member until June 2026; Molecular Templates Inc. (NASDAQ: MTEM), where she served until December 2024; TransCelerate Biopharma Inc., where she served as Vice Chair; and the Fred Hutchinson Cancer Center, where she served as Co-Chair of the Board of Advisors and Chair of the Science & Technology Advisory Committee. Prior to her board service, Dr. Sanders held senior executive positions at Juno Therapeutics (acquired by Celgene/BMS), where she served as Executive Vice President of Development Operations and Strategic Advisor to the Chief Medical Officer and contributed to the global development of Breyanzi® (lisocabtagene maraleucel). At Genentech/Roche, she held several senior leadership roles, including Senior Vice President & Global Head of Clinical Operations, leading a team of 2,500 professionals, and Senior Vice President of Global Biometrics & Innovation, leading a team of 1,100 professionals. She was a member of the Late Stage Portfolio Committee and Co-Chair of the Roche/Chugai Joint Portfolio Management Committee and contributed to the development and approval of multiple therapies, including Herceptin®, Rituxan®, Avastin®, and Lucentis®. Earlier in her career, she held biostatistics positions at Schering-Plough and Centocor. Dr. Sanders holds a Ph.D. and M.S. in Statistics from The Wharton School, University of Pennsylvania, and M.S. and B.S. degrees in Statistics from the University of the Philippines.

Calidi Biotherapeutics, Inc. Stock Price

CLDI Share Price Performance

CLDI Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Calidi Biotherapeutics, Inc. Key Details

About CLDI

Recent CLDI News & Updates

Calidi Biotherapeutics Presents New Data On CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 At The T-Cell Engager Therapeutic Summit

Calidi Biotherapeutics, Inc. Announces Appointment of Corsee Sanders to Board of Directors and Member of the Audit Committee, Effective June 17, 2026

Calidi Biotherapeutics, Inc. Receives Positive Pre-Ind Feedback From US FDA For CLD-401 And Advances Ind-Enabling Studies Towards First-In-Human Study

Recent updates

Calidi Biotherapeutics, Inc. Competitors

Sonoma Pharmaceuticals

Soligenix

NuCana

Aptevo Therapeutics